Insights On CONTRACT PHARMA MANUFACTURING
-
Outsourcing Not Plug-And-Play
5/15/2024
Joanne Beck, Chief Technology Officer, Aerium Therapeutics, starts our Outsourced Pharma Live with a caution: Working with CDMOs is less like a plug-and-play model, and more like a custom-fit set of activities.
-
Tackling Antimicrobial Resistance
5/14/2024
Learn how three companies collaborated to develop and new antibiotic to address the increasing development of antimicrobial resistance (AMR) that threatens the global health landscape.
-
A New Centre For Continuous mRNA Manufacturing
5/14/2024
Explore how a partnership between academia, regulatory agencies, and manufacturing organizations has the potential to reshape the way we produce and distribute mRNA-based therapies.
-
Cell And Virus Banking In OV Development And Manufacturing
5/14/2024
Delve into the exciting potential of OVs, including the critical role of cell and virus seed banks, and discover key considerations for establishing cell and virus banks for OV production.
-
Key Elements Of Process, Analytical Development To Support Tech Transfer
5/13/2024
Tech Transfer for biologic medicinal products is complex - filled with potential pitfalls, hazards, and breakpoints. Review strategies and methodologies for seamless technology transfer to your CDMO.
-
BD Innovation For Subcutaneous Delivery Of Large-Volume Complex Biologics
5/9/2024
Explore the key findings of a new wearable injector clinical trial, including its positive impact on patient experience and the broader benefits of wearable injectors for chronic disease management.
-
Key Considerations In Optimizing Downstream Process Development For mAbs
5/8/2024
Optimizing downstream process development for mAbs requires scientific expertise, careful planning, and rigorous testing. Delve into the essential steps and learn how to deliver high-quality mAbs.
-
Best Practices To Adapt And Improve Quality Control Programs For CGTs
5/8/2024
Cell and gene therapies require adaptive and advanced assays for characterization and safety assessments; in many instances, the assays historically used for biologics must diversify to accommodate them.
-
Overcome The Challenges Of Designing A QC Program For New Modalities
5/8/2024
Stringent QC release testing throughout biologic production, as mandated by global health authorities, ensures product safety and quality through robust evaluations of identity, purity, potency, and critical quality attributes.
-
6 Key Questions When Selecting Your Cell Banking Manufacturing Partner
5/8/2024
Evaluating a potential cell banking partner's experience, testing capabilities, and approach to material management can help guarantee the quality and consistency of your therapeutic cells.